Suboxone

RSS

Withdrawn

This medicine's authorisation has been withdrawn

buprenorphine / naloxone
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 11 September 2026, the European Commission withdrew the marketing authorisation for Suboxone (buprenorphine / naloxone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Indivior Europe Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Suboxone was granted marketing authorisation in the EU on 26 September 2006 for the substitution treatment of opioid drug dependence, within a framework of medical, social and psychological treatment. Suboxone was used in adults and adolescents over 15 years of age who had agreed to be treated for addiction.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011.

Several therapeutic alternatives remain available, as either buprenorphine alone or buprenorphine in combination with naloxone, in different pharmaceutical forms.

български (BG) (154.63 KB - PDF)

Skatīt

español (ES) (126.92 KB - PDF)

Skatīt

čeština (CS) (150.58 KB - PDF)

Skatīt

dansk (DA) (127.12 KB - PDF)

Skatīt

Deutsch (DE) (130.69 KB - PDF)

Skatīt

eesti (ET) (123.34 KB - PDF)

Skatīt

ελληνικά (EL) (155.89 KB - PDF)

Skatīt

français (FR) (128 KB - PDF)

Skatīt

hrvatski (HR) (150.39 KB - PDF)

Skatīt

italiano (IT) (126.79 KB - PDF)

Skatīt

latviešu (LV) (168.28 KB - PDF)

Skatīt

lietuvių (LT) (152 KB - PDF)

Skatīt

magyar (HU) (149.14 KB - PDF)

Skatīt

Malti (MT) (152.23 KB - PDF)

Skatīt

Nederlands (NL) (127.66 KB - PDF)

Skatīt

polski (PL) (153.03 KB - PDF)

Skatīt

português (PT) (129.04 KB - PDF)

Skatīt

română (RO) (148.26 KB - PDF)

Skatīt

slovenčina (SK) (152.34 KB - PDF)

Skatīt

slovenščina (SL) (149.23 KB - PDF)

Skatīt

suomi (FI) (125.71 KB - PDF)

Skatīt

svenska (SV) (126.4 KB - PDF)

Skatīt

Product information

български (BG) (1.02 MB - PDF)

Skatīt

español (ES) (759.51 KB - PDF)

Skatīt

čeština (CS) (1001.99 KB - PDF)

Skatīt

dansk (DA) (886.16 KB - PDF)

Skatīt

Deutsch (DE) (912.04 KB - PDF)

Skatīt

eesti (ET) (973.17 KB - PDF)

Skatīt

ελληνικά (EL) (1.07 MB - PDF)

Skatīt

français (FR) (1016.58 KB - PDF)

Skatīt

hrvatski (HR) (959.44 KB - PDF)

Skatīt

italiano (IT) (898.18 KB - PDF)

Skatīt

latviešu (LV) (968.27 KB - PDF)

Skatīt

lietuvių (LT) (949.26 KB - PDF)

Skatīt

magyar (HU) (1018.05 KB - PDF)

Skatīt

Malti (MT) (1017.44 KB - PDF)

Skatīt

Nederlands (NL) (876.74 KB - PDF)

Skatīt

polski (PL) (1016.8 KB - PDF)

Skatīt

português (PT) (890.47 KB - PDF)

Skatīt

română (RO) (1.03 MB - PDF)

Skatīt

slovenčina (SK) (1.02 MB - PDF)

Skatīt

slovenščina (SL) (950.21 KB - PDF)

Skatīt

suomi (FI) (887.75 KB - PDF)

Skatīt

svenska (SV) (889.06 KB - PDF)

Skatīt

Íslenska (IS) (870.77 KB - PDF)

Skatīt

norsk (NO) (868.11 KB - PDF)

Skatīt
Latest procedure affecting product information:PSUSA/00002113/202309
24/07/2024
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (87.43 KB - PDF)

Skatīt

español (ES) (65 KB - PDF)

Skatīt

čeština (CS) (104.93 KB - PDF)

Skatīt

dansk (DA) (66.01 KB - PDF)

Skatīt

Deutsch (DE) (66.19 KB - PDF)

Skatīt

eesti (ET) (65.48 KB - PDF)

Skatīt

ελληνικά (EL) (87.8 KB - PDF)

Skatīt

français (FR) (68.57 KB - PDF)

Skatīt

hrvatski (HR) (82.73 KB - PDF)

Skatīt

italiano (IT) (63.93 KB - PDF)

Skatīt

latviešu (LV) (85.72 KB - PDF)

Skatīt

lietuvių (LT) (85.09 KB - PDF)

Skatīt

magyar (HU) (74.75 KB - PDF)

Skatīt

Malti (MT) (88.02 KB - PDF)

Skatīt

Nederlands (NL) (64.63 KB - PDF)

Skatīt

polski (PL) (89.14 KB - PDF)

Skatīt

português (PT) (65.5 KB - PDF)

Skatīt

română (RO) (75.31 KB - PDF)

Skatīt

slovenčina (SK) (103.63 KB - PDF)

Skatīt

slovenščina (SL) (103.72 KB - PDF)

Skatīt

suomi (FI) (64.66 KB - PDF)

Skatīt

svenska (SV) (86.31 KB - PDF)

Skatīt

Íslenska (IS) (65.52 KB - PDF)

Skatīt

norsk (NO) (65.84 KB - PDF)

Skatīt

Product details

Name of medicine
Suboxone
Active substance
  • buprenorphine
  • naloxone
International non-proprietary name (INN) or common name
  • buprenorphine
  • naloxone
Therapeutic area (MeSH)
Opioid-Related Disorders
Anatomical therapeutic chemical (ATC) code
N07BC51

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Authorisation details

EMA product number
EMEA/H/C/000697
Marketing authorisation holder
Indivior Europe Limited

27 Windsor Place
Dublin 2
Ireland

Opinion adopted
27/07/2006
Marketing authorisation issued
26/09/2006
Withdrawal of marketing authorisation
11/09/2026
Revision
24

Assessment history

This page was last updated on

Share this page